Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH, marking a significant milestone in the company's globalization strategy [1] Group 1: Acquisition Details - The acquisition will occur in phases, allowing Guichuang Tongqiao to eventually acquire all remaining shares and corresponding rights of Optimed [1] - This transaction is expected to enhance Guichuang Tongqiao's global operational and delivery capabilities, providing high-quality and affordable innovative products and solutions to more patients [1] Group 2: Global Market Expansion - The deal will support Guichuang Tongqiao's international strategy, accelerating its expansion in Europe and other key overseas markets [2] - Post-transaction, both companies will integrate their commercialization platforms, including sales networks and customer service systems, to create a unified and efficient global operation [2] Group 3: Optimed Overview - Optimed is a German medical technology company focused on minimally invasive vascular and urological intervention devices, established in 1996 and currently serving over 70 countries [3] - The company has a strong reputation in the peripheral venous treatment sector, with its sinus-Venous stent product validated in the STEVECO clinical trial, showing significant improvements in patient quality of life [3] Group 4: Operational Synergies - The acquisition will enhance Guichuang Tongqiao's R&D and manufacturing capabilities in overseas markets, leveraging Optimed's production base in Germany [4] - Both companies will collaborate to improve product quality and operational efficiency, while integrating R&D resources and clinical networks to expedite the launch of clinically valuable innovative products [4] Group 5: Leadership Insights - The Chairman and CEO of Guichuang Tongqiao emphasized that the acquisition is a crucial step in the company's international strategy, aiming to create an integrated operational platform across China and Europe [5] - The CEO of Optimed highlighted the need for a more comprehensive international platform to better serve global customers and achieve long-term growth, noting the complementary strengths of both companies [5]

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH, marking a significant milestone in the company's globalization strategy [1] Group 1: Acquisition Details - The acquisition will occur in phases, allowing Guichuang Tongqiao to eventually acquire all remaining shares and corresponding rights of Optimed [1] - This transaction is expected to enhance Guichuang Tongqiao's global operational and delivery capabilities, benefiting more patients with high-quality and affordable innovative products [1] Group 2: Global Commercialization Strategy - The deal will support the deep implementation of Guichuang Tongqiao's international strategy, accelerating its expansion in Europe and other key overseas markets [2] - Post-transaction, both companies will integrate their commercialization platforms, including existing sales networks and academic promotion teams, to create a unified and efficient global operation system [2] Group 3: Optimed Overview - Optimed is a German medical technology company focused on minimally invasive vascular and urological intervention devices, established in 1996 and currently serving over 70 countries [3] - The company has a strong reputation in the peripheral venous treatment field, with its sinus-Venous stent product validated in the STEVECO clinical trial, showing significant improvements in patient quality of life compared to conservative treatment [3] Group 4: Operational Synergies - The acquisition will enhance Guichuang Tongqiao's R&D and manufacturing capabilities in overseas markets, leveraging Optimed's production base in Germany to stabilize and efficiently serve European and other key markets [4] - Both companies will collaborate on production and operations to improve product quality and operational efficiency, while integrating R&D resources to expedite the launch of clinically valuable innovative products [4] Group 5: Leadership Insights - The Chairman and CEO of Guichuang Tongqiao emphasized that the acquisition is a crucial step in the company's international strategy, aiming to create an integrated operational platform across China and Europe [5] - The CEO of Optimed highlighted the need for a more comprehensive international platform to better serve global customers and achieve long-term development, noting the complementary strengths between the two companies [5]

Core Viewpoint - The company Guichuang Tongqiao (02190.HK) has entered into an agreement to acquire a 49% stake in E-Med Solutions for approximately €18.375 million (around RMB 149 million), with options to acquire the remaining shares in the future [1][2]. Group 1: Acquisition Details - The acquisition agreement was signed on January 16, 2026, with the company acting as the buyer and E-Med Solutions as the seller [1]. - The total consideration for the acquisition is subject to further adjustments [1]. - The target company, Optimed Holding GmbH, is a limited liability company established under German law and is currently wholly owned by the seller [2]. Group 2: Target Company Overview - Optimed Holding GmbH and its subsidiaries, including Optimed Medizinische Instrumente GmbH, focus on the development, manufacturing, and distribution of medical technology products and solutions [2]. - The main operating subsidiary, Optimed Medizinische Instrumente GmbH, is headquartered in Germany and specializes in high-quality medical products for minimally invasive vascular and urological instruments [2]. - Optimed has a comprehensive product portfolio in the peripheral venous stent market, including devices for the iliac vein, iliac artery bifurcation, inferior vena cava, and aorta [2]. Group 3: Strategic Implications - Following the completion of the acquisition, the company and the target company will integrate their commercialization platforms, including sales and marketing networks, promotional capabilities, and customer service infrastructure [2]. - The target company will serve as the exclusive distributor for all vascular products outside of mainland China [2]. - Rüdiger Hausherr will continue as CEO of Optimed and report to Dr. Zhao Zhong, the company's chairman and CEO, which is expected to enhance and accelerate the company's international sales capabilities and global expansion [2].

Core Viewpoint - The company has entered into an agreement to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy [1]. Group 1: Acquisition Details - The acquisition agreement allows the company to purchase 49% of Optimed Holding GmbH, with an option to acquire the remaining shares from other shareholders [1]. - Post-acquisition, Optimed will not become a subsidiary, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition represents a key milestone in the company's long-term commitment to global expansion, enhancing its competitive position and influence in international markets [1]. - Integration with Optimed's sales network will accelerate the global application of innovative vascular solutions, leveraging strong relationships with European medical experts [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency [2]. - The company aims to fully leverage its R&D capabilities through an integrated global commercialization platform, providing advanced medical solutions to patients and healthcare professionals worldwide [2]. Group 3: Operational Integration - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China [3]. - Rüdiger Hausherr will continue as CEO of Optimed, reporting to the company's Chairman and CEO, Dr. Zhao Zhong, which will further accelerate the company's global expansion efforts [3].

Core Viewpoint - The acquisition of a 49% stake in Optimed Holding GmbH by the company marks a significant milestone in its long-term commitment to global expansion and aims to enhance its competitive position in the international market [1][2]. Group 1: Acquisition Details - The company has entered into a purchase agreement to acquire 49% of Optimed Holding GmbH for approximately €18.375 million [1]. - The agreement includes an option for the company to acquire the remaining shares from other shareholders at its discretion [1]. - Post-acquisition, Optimed will not become a subsidiary of the company, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition is a key milestone for the company's entry into the European and global markets, facilitating asset integration to accelerate international strategy deployment and diversify the product portfolio [2]. - The integration with Optimed's sales network will enhance the global application of innovative vascular solutions, leveraging strong relationships with European medical experts to expedite clinical processes and product launches [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency while expanding production capacity in Germany [2]. Group 3: R&D and Commercialization - The integrated global commercialization platform will fully leverage the company's R&D capabilities, aiming to provide cutting-edge medical solutions to patients and healthcare professionals worldwide [3]. - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside mainland China, with Rüdiger Hausherr continuing as CEO of Optimed [3].

Core Viewpoint - The company is set to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy and enhancing its competitive position in the medical technology sector [1][2]. Group 1 - The acquisition represents a key milestone in the company's long-term commitment to global expansion, facilitating entry into European and global markets [2]. - The integration of assets is expected to accelerate the company's international strategy, diversify its product portfolio, and expand its global distribution network [2]. - The transaction aims to create significant manufacturing and operational synergies between Germany and China, enhancing product quality and operational efficiency [2]. Group 2 - The acquisition will enable the company to fully leverage its efficient R&D capabilities, expanding its innovative solutions to global markets [3]. - Post-acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, to enhance international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China, significantly boosting the company's international sales efforts [3].

Zylox-Tonbridge Medical Technology Co., Ltd. 歸創通橋醫療科技股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2190） 須予披露交易 收購目標公司之49%股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 緒言 於 2026 年 1 月 16 日（交 易 時 段 前，香 港 時 間），本 公 司（作 為 買 方）與E-Med Solutions（作為賣方）訂立買賣協議。根據買賣協議，買方同意收購目標公司 之49%股權，總代價約為18.375百萬歐元（相當於人民幣149.41百萬元）（可予進 一步調整）。根據買賣協議，買方亦獲授期權，可由買方酌情行使，以向目 標公司其他股東收購目標公司之餘下股權。 建議收購事項完成後，目標公司將不會成為本公司之附屬公司，且目標公司 之財務業績將不會併入本公司之財務報表。 上市規則之涵義 由於有關買賣協議項下擬進 ...

生物医药与健康产业是珠海"4+3"产业集群的重要组成部分，相关企业的发展备受珠海社会各界关注。1 月8日，归创通桥医疗科技股份有限公司在珠海高新区通桥医疗创新基地，举办投资者开放日活动，围 绕行业发展趋势、公司战略布局及创新产品进展展开深入探讨。 归创通桥董事长赵中介绍公司情况。 据悉，本次活动所在的珠海创新基地，于2022年动工建设，并于近期实现建成投产。项目占地约16000 ㎡，规划总建筑面积约58000㎡，计划总投资20亿元，建设涵盖研发厂房、办公及宿舍等功能配套，主 要针对几十项产品的研发、取证及规模化生产，搭建颅内植介入支架成型及加工、导管成型及制造、弹 簧圈等多条生产线。 赵中表示，该项目是公司集研发、制造与产业化于一体的重要平台，为公司推进创新成果转化及全球化 发展提供了坚实支撑。"项目能够满足我们接下来的产能需求，为公司的全方位发展奠定了很好的基 础。我们也很高兴能借此契机，向投资人和业界朋友展示我们的全新面貌。" 立足珠海十年，公司对珠海的产业发展环境有何评价？赵中表示："珠海城市环境很好，高新区也有各 种各样的优惠政策，对公司的发展与基地的建设给予了大力支持，我们很感谢政府部门这么多年对我 ...

| 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 336,350,744 | RMB | | | 1 RMB | | 336,350,744 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 336,350,744 | RMB | | | 1 RMB | | 336,350,744 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 歸創通橋醫療科技股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 2. 股份分類 | ...

Group 1 - The stock of Guichuang Tongqiao (02190.HK) experienced a significant intraday increase, rising over 5% at one point and closing with a gain of 3.76% at HKD 23.2 [2] - The trading volume reached HKD 15.39 million, indicating active market participation [2]